A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases

    Not Recruiting
  • End date
    Apr 2, 2024
  • participants needed
  • sponsor
    Janssen Research & Development, LLC
Updated on 23 May 2022
antiandrogen therapy
androgen suppression
prostate specific antigen
metastatic prostate cancer
recurrent prostate cancer
adenocarcinoma of prostate
prostate cancer metastatic
non-metastatic prostate cancer


Main Study: The purpose of main study is to assess if the combination of apalutamide and androgen deprivation therapy (ADT) in participants with high-risk localized prostate cancer improves the biochemical recurrence (BCR) free rate.

Sub-study: The purpose of the sub-study is to assess if the co administration of apalutamide and relugolix is able to maintain castrate levels of testosterone.

Condition Prostatic Neoplasms
Treatment ADT, Apalutamide, Relugolix
Clinical Study IdentifierNCT04523207
SponsorJanssen Research & Development, LLC
Last Modified on23 May 2022

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note